G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials

Vista senzilla d'ítem
dc.contributor.authorBellver Sanchis, Aina
dc.contributor.authorRibalta Vilella, Marta
dc.contributor.authorIrisarri, Alba
dc.contributor.authorGehlot, Pinky
dc.contributor.authorChoudhary, Bhanwar Singh
dc.contributor.authorJana, Abhisek
dc.contributor.authorVyas, Vivek Kumar
dc.contributor.authorBanerjee, Deb Ranjan
dc.contributor.authorPallàs i Llibería, Mercè, 1964-
dc.contributor.authorGuerrero López, Ana
dc.contributor.authorGriñán Ferré, Christian
dc.date.accessioned2026-05-14T08:06:31Z
dc.date.available2026-05-14T08:06:31Z
dc.date.issued2025-01-06
dc.date.updated2026-05-14T08:06:33Z
dc.description.abstractThis review provides a comprehensive overview of the role of G9a/EHMT2, focusing on its structure and exploring the impact of its pharmacological and/or gene inhibition in various neurological diseases. In addition, we delve into the advancements in the design and synthesis of G9a/EHMT2 inhibitors, which hold promise not only as a treatment for neurodegeneration diseases but also for other conditions, such as cancer and malaria. Besides, we presented the discovery of dual therapeutic approaches based on G9a inhibition and different epigenetic enzymes like histone deacetylases, DNA methyltransferases, and other lysine methyltransferases. Hence, findings offer valuable insights into developing novel and promising therapeutic strategies targeting G9a/EHMT2 for managing these neurological conditions.
dc.format.extent31 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec753158
dc.identifier.issn0198-6325
dc.identifier.pmid39763018
dc.identifier.urihttps://hdl.handle.net/2445/229502
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/med.22096
dc.relation.ispartofMedicinal Research Reviews, 2025, vol. 45, num.3, p. 985-1015
dc.relation.urihttps://doi.org/10.1002/med.22096
dc.rightscc by (c) Bellver Sanchis, Aina et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
dc.subject.classificationNeurogenètica
dc.subject.classificationFarmacogenètica
dc.subject.otherNeurogenetics
dc.subject.otherPharmacogenetics
dc.titleG9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
874931.pdf
Mida:
3.16 MB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Institut de Neurociències (UBNeuro))